OPNT - オピアント・ファ―マシュ―ティカルズ (Opiant Pharmaceuticals Inc.)

OPNTのニュース

   Teva Reaches Agreement With Rhode Island to Settle Opioid-Related Claims  2022/03/21 18:55:00 Kwhen Finance
   Opiant Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation  2022/03/21 11:52:53 Seeking Alpha
   Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q4 2021 Results - Earnings Call Transcript  2022/03/15 23:00:02 Seeking Alpha
   Opiant Pharmaceuticals GAAP EPS of $0.11 beats by $0.01, revenue of $13.8M beats by $0.54M  2022/03/15 20:09:33 Seeking Alpha
Opiant Pharmaceuticals press release (NASDAQ:OPNT): Q4 GAAP EPS of $0.11 beats by $0.01.Revenue of $13.8M (+39.1% Y/Y) beats by $0.54M.
   Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update  2022/03/15 20:05:00 GlobeNewswire
SANTA MONICA, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and twelve months ended December 31, 2021, and provided a corporate update. Recent highlights include:
   Opiant Pharmaceuticals, Inc. to Post FY2021 Earnings of $0.26 Per Share, Oppenheimer Forecasts (NASDAQ:OPNT)  2021/12/15 06:18:42 Transcript Daily
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Oppenheimer issued their FY2021 earnings estimates for shares of Opiant Pharmaceuticals in a research report issued on Wednesday, December 8th. Oppenheimer analyst L. Gershell expects that the technology company will earn $0.26 per share for the year. Oppenheimer has a Outperform rating and a $42.00 price target on the stock. []
   Wells Fargo & Company MN Grows Stock Holdings in Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)  2021/12/12 10:18:42 Dakota Financial News
Wells Fargo & Company MN boosted its holdings in shares of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) by 0.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 251,007 shares of the technology companys stock after purchasing an additional 925 shares during the []
   Opiant Pharmaceuticals (NASDAQ:OPNT) Earns Outperform Rating from Analysts at Oppenheimer  2021/12/08 21:38:42 Transcript Daily
Investment analysts at Oppenheimer initiated coverage on shares of Opiant Pharmaceuticals (NASDAQ:OPNT) in a research report issued on Wednesday, The Fly reports. The brokerage set an outperform rating on the technology companys stock. NASDAQ OPNT traded up $2.26 on Wednesday, hitting $32.20. 260 shares of the company were exchanged, compared to its average volume of []
   Why U.S. Fentanyl Deaths Will Keep Rising  2021/12/08 19:38:54 RealClearPolitics
Overdose crisis that killed over 100,000 Americans in one year is ''all about fentanyl'', says Roger Crystal of Opiant Pharmaceuticals
   $14.38 Million in Sales Expected for Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) This Quarter  2021/12/06 09:40:41 Dakota Financial News
Analysts forecast that Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) will announce sales of $14.38 million for the current quarter, according to Zacks. Two analysts have made estimates for Opiant Pharmaceuticals earnings, with estimates ranging from $14.15 million to $14.60 million. Opiant Pharmaceuticals posted sales of $9.92 million during the same quarter last year, which would indicate a []
   Opiant Pharmaceuticals, Inc. to Post FY2021 Earnings of $0.26 Per Share, Oppenheimer Forecasts (NASDAQ:OPNT)  2021/12/15 06:18:42 Transcript Daily
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Oppenheimer issued their FY2021 earnings estimates for shares of Opiant Pharmaceuticals in a research report issued on Wednesday, December 8th. Oppenheimer analyst L. Gershell expects that the technology company will earn $0.26 per share for the year. Oppenheimer has a Outperform rating and a $42.00 price target on the stock. []
   Wells Fargo & Company MN Grows Stock Holdings in Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)  2021/12/12 10:18:42 Dakota Financial News
Wells Fargo & Company MN boosted its holdings in shares of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) by 0.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 251,007 shares of the technology companys stock after purchasing an additional 925 shares during the []
   Opiant Pharmaceuticals (NASDAQ:OPNT) Earns Outperform Rating from Analysts at Oppenheimer  2021/12/08 21:38:42 Transcript Daily
Investment analysts at Oppenheimer initiated coverage on shares of Opiant Pharmaceuticals (NASDAQ:OPNT) in a research report issued on Wednesday, The Fly reports. The brokerage set an outperform rating on the technology companys stock. NASDAQ OPNT traded up $2.26 on Wednesday, hitting $32.20. 260 shares of the company were exchanged, compared to its average volume of []
   Why U.S. Fentanyl Deaths Will Keep Rising  2021/12/08 19:38:54 RealClearPolitics
Overdose crisis that killed over 100,000 Americans in one year is ''all about fentanyl'', says Roger Crystal of Opiant Pharmaceuticals
   $14.38 Million in Sales Expected for Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) This Quarter  2021/12/06 09:40:41 Dakota Financial News
Analysts forecast that Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) will announce sales of $14.38 million for the current quarter, according to Zacks. Two analysts have made estimates for Opiant Pharmaceuticals earnings, with estimates ranging from $14.15 million to $14.60 million. Opiant Pharmaceuticals posted sales of $9.92 million during the same quarter last year, which would indicate a []

calendar